To find new compounds with potential neuroprotective activity, we have designed, synthesized, and characterized a series of neural nitric oxide synthase (nNOS) inhibitors with a kynurenamine structure. Among them,acetamide is the main melatonin metabolite in the brain and shows the highest activity in the series, with an inhibition percentage of 65% at a 1 mM concentration. The structure-activity relationship of the new series partially reflects that of the previously reported 2-acylamido-4-(2-amino-5-methoxyphenyl)-4-oxobutyric acids, endowed with a kynurenine-like structure. Structural comparisons between these new kinurenamine derivatives, kynurenines, and 1-acyl-3-(2-amino-5-methoxyphenyl)-4,5-dihydro-1H-pyrazole derivatives also reported confirm our previous model for the nNOS inhibition.
Introduction
N-methyl-D-aspartate (NMDA) receptors are a subtype of receptors that, activated by glutamate, gather the influx of Ca 2+ into the neuronal cell, along with a flux of other ions such as Na + and K + . 1 An overstimulation of the NMDA receptors produces an accumulation of intracellular Ca 2+ that, in turn, activates a series of enzymes such as lipases, proteases, and nitric oxide synthase (NOS), thus leading to the formation of reactive oxygen species (ROS), responsible for the neuronal damage. [2] [3] [4] Nitric oxide (NO) is a well-known biologically active compound that acts as a cell messenger with important regulatory functions in the nervous, immune, and cardiovascular systems. 5 In mammals, NO is synthesized from L-arginine in various cell types (neurons, 6 endothelial cells, 7 and macrophages 8, 9 ) by a family of nitric oxide synthase (NOS) isoenzymes. 10, 11 The constitutive endothelial (eNOS) and neural (nNOS) isoforms are calcium/calmodulin dependent and are physiologically activated by hormones or neurotransmitters that increase the intracellular calcium concentration.
In contrast, the inducible (iNOS) isoform is activated by basal intracellular calcium concentrations, and once expressed, it remains permanently activated, yielding high NO concentrations. This mechanism is part of the normal immune response against invading pathogens and neoplastic cells. 12 Although NO is not involved in the synaptic transmission under normal conditions, an excessive NO production by some of the NOS-isoenzymes may be detrimental. Thus, it is well-known that an overproduction of NO produces neurotoxicity, and this fact has been associated with several neurological disorders such as Alzheimer's disease, 13, 14 amyotrophic lateral sclerosis, 15 and Huntington's disease. 16 For this reason, a recent strategy in the development of successful neuroprotective agents is orientated toward the synthesis of new structures that interfere with some step of the complex chemical signaling system involving NOS, including the inhibition of the enzyme itself. It has been shown that melatonin (1), the main compound secreted by the pineal gland, can inhibit the nNOS activity in rat striatum in a dose-dependent manner. 17 As a consequence of the nNOS inhibition, melatonin also inhibits the NMDA-induced excitation, 18 and it has been proven that this neuroprotective action is unrelated to known melatonin receptors. 19 In the brain, melatonin is metabolized by the action of the indolamine-2,3-dioxygenase (IDO) to afford the N 1 -acetyl-N 2 -formyl-5-methoxykynurenine (AFMK). This metabolite is further transformed into N-acetyl-5-methoxykynurenamine (aMK), and this is one of the more important metabolic pathways of melatonin in mammalians. 20, 21 On the other hand, the action of melatonin can be due to one of these metabolites. 22 Recently, we have synthesized and evaluated a series of kynurenine derivatives of general formulae 2, showing a significant nNOS inhibitory activity. 23 In these compounds, the side-chain conformational mobility can be restricted by the formation of an intramolecular hydrogen bond between the 2′-NH 2 and the carbonyl group, and as a consequence of this restriction, the kynurenine derivative can mimic the active conformation of melatonin when it interacts with its biological target. 23 In a more recent paper, we have described the synthesis of a series of 4,5-dihydro-1H-pyrazole derivatives of general formula 3 that constitute a new type and potent nNOS inhibitors. 24 In this paper, we describe the synthesis of a series of kynurenamine derivatives 4, among which is the melatonin metabolite aMK (4a, R 1 ) OMe, R 2 ) Me), that show good nNOS inhibitory activity and could be used as a template in the development of new agents with a neuroprotective mechanism similar to that of melatonin. Due to their similarity with kinurenine, the new kynurenamine derivatives were also tested as inhibitors of the kynurenine 3-hydroxylase (KYN3OH), a key enzyme in the kynurenine pathway, showing that all compounds are inactive against this enzyme.
Chemistry
Scheme 1 represents the general synthetic pathway for all final kynurenamines included in Table 1 . 5-Metoxi-and 5-chloro-2-nitrophenyl vinyl ketones 5a and 5b, prepared as previously reported 24 from 5-chloroand 5-hydroxy-2-nitrobenzaldehyde, respectively, were reacted with phthalimide 25 in the presence of NaMeO to afford the intermediates 6a and 6b with very high yields (90-92%).
The ketone group of 6a and 6b is protected by reaction with ethylene glycol in the presence of p-toluenesulfonic acid to yield the dioxolane derivatives 7a-b (85% in both cases). This protection is necessary because when 6a or 6b are directly treated with hydrazine, the phtalimide group opens, and the intermediate hydrazine derivative cyclisizes to afford the intermediate pyrazoline type 8, which can be converted into the pyrazoline derivative 3 in several steps. 24 The reaction of 7a and 7b with hydrazine opens the phthalimide moiety, and further acidification (HCl) of the reaction mixture allows the hydrolysis of the dioxolane group to yield the corresponding -aminoketones 9a and 9b, which were not isolated. Acylation in situ of 9a and 9b by reaction with acetic anhydride or with the corresponding acyl chloride gives rise to the 2′-NO 2 derivatives 10a-l. Yields vary from 70 to 90% in all compounds.
Finally, the reduction of the 2′-NO 2 groups in 10a-l allows for the preparation of the corresponding kynurenamine derivative 4a-l. This reduction was accomplished by catalytic hydrogenation (H 2 , Pd/C) in 10a-i (quantitative yield) and by reaction with Fe/FeSO 4 in 10j-l (95%) to avoid dechlorination. Figure 1 illustrate the nNOS inhibition in the presence of a 1 mM concentration of each kynurenamine 4. All compounds show good nNOS inhibition, depending on the substitution on both R 1 and R 2 groups. The influence of R 2 on the activity seems to be clear because, in general, it can be observed that an increment in the volume of R 2 decreases the inhibitory activity. Thus, the change of the Me group by Et, Pr, or Bu decreases steadily the percentage of inhibition. The insertion of a cyclopropyl or a phenyl group in R 2 is also detrimental for the activity. In relation to R 1 , it can be observed that compounds with R 1 ) OMe are about 2 times more active than the corresponding ones with R 1 ) Cl, indicating that an electron-withdrawing substituent is detrimental for the activity. Unfortunately, we have not found any quantitative relationships between the volume of the substituent R 2 or the nature of R 1 and the inhibitory activity. Table 1 and Figure 1 also illustrate the activity of compounds type 4 against KYN3OH. The inhibition of this enzyme has been proposed as a potentially useful strategy for neuroprotection 26 because KYN3OH inhibitors decrease the brain concentration of the neurotoxic quinolinic acid and 3-hydroxykynurenine while increasing the biosynthesis of the neuroprotective kynurenic acid. It can be observed that none of the new compounds showed a significant effect on this enzyme.
Results and Discussion
In a previous paper, 23 we have described the effects of several kynurenine derivatives of general structure 2 on the excitatory response of striatal neurons to sensorimotor cortex (SMCx) stimulation, an experimental paradigm involving the activation of the NMDA subtype of glutamatergic receptor. Among these compounds, two of them (2a, R ) Me, and 2b, R ) Pr) showed a strong inhibitory effect on the striatal excitation. Our previous results indicated that there was no response when these compounds were iontophoretized onto a silent neuron in the absence of a NMDA ejection, 23 thus suggesting that they act by reducing the excitatory response elicited by NMDA activation. 2a and 2b are also able to significantly reduce the nNOS activity. 23 Kynurenines 2a and 2b have also been tested as inhibitors of the kynurenine 3-hydroxylase (KYN3OH). 24 The most interesting result from these experiments was that 2a and 2b showed no inhibitory activity against this enzyme. Because both compounds are able to inhibit both the NMDA-dependent excitability and nNOS activity, we concluded that their inhibitory properties are due to the nNOS inhibition.
2a and 2b bear a 2′-NH 2 group on the benzene ring, and this feature seems to be necessary for the nNOS inhibition because the removal of this group caused a significant decrease in the inhibitory response. The 2′-NH 2 group can condition the inhibitory activity in two different ways: (i) by restricting the conformational mobility of the kynurenine side chain and, hence, allowing the side chain to mimic melatonin, a known nNOS inhibitor, and (ii) by forming an additional hydrogen bond with some critical residues of nNOS when the complex is formed.
4,5-Dihydro-1H-pyrazole derivatives 3 were designed as more rigid nNOS inhibitors bearing the pharmacophoric features of kynurenines 2. 24 These molecules bear the 2′-NH 2 group that forms the intramolecular hydrogen bond with the N-2 pyrazole atom and can also produce a favorable interaction with the enzyme. On the other hand, the pyrazole ring confers rigidity to the molecule, and the final amide moiety can act in a way similar to that of the amide group of kynurenines 2. We have found that compounds 3 show good nNOS inhibition, depending on the nature of both R 1 and R 2 substituents. Even more, compounds 3 are inactive against KYN3OH, indicating that their potential neuroprotective properties are due again to the nNOS inhibition.
From the comparison of kynurenines 2 and dihydropyrazoles 3, a pharmacophore model ( Figure 3 ) for the interaction with nNOS has been developed. 24 This model includes the aromatic ring, the 2′-NH 2 group, and the terminal amide CO fragment and can explain the structure-activity relationships for both families of compounds. Briefly, the model for the interaction includes: (i) a pocket in the enzyme that accommodates the benzene rings (red arc); (ii) a hydrogen-bond acceptor residue for the interaction with the free NH bond of the 2′-NH 2 group (blue arrow). (iii) a hydrogen-bond donor residue that can interact with the amide oxygen atom of both kynurenine and pyrazole derivatives (red arrow), and (iv) two different zones near the binding pocket that accommodates the R 2 substituent of kynurenines 2 and pyrazolines 3. Because an increment in the R 2 volume in kynurenines provokes a decrease in activity, these molecules must orientate the R 2 substituent to a region with a small steric tolerance. On the contrary, the R 2 substituent in pyrazolines must be orientated to a zone sterically allowed.
Conformational analysis of kynurenamines 4 indicates a behavior similar to that of kynurenines 2. Molecular modeling studies were performed using the Sybyl software 27 running on a Silicon Graphics workstation. Three-dimensional models of all compounds Each value is the mean of three experiments performed by triplicate in homogenates of four rat striata in each one. *P < 0.01 and **P < 0.001 vs control.
were built from a standard fragment library, and their geometries were subsequently optimized using the Tripos force field 28 including the electrostatic term calculated from Gasteiger and Hü ckel 29 charges ( ) 1, distance dependent). The method of Powell 30 included in the Maximin2 procedure was used for energy minimization until the gradient value was smaller than 0.01 kcal/mol‚Å 2 .
After the initial optimization, a conformational search of each compound using the Sybyl Gridsearch utility has been performed to locate the most stable conformer. With this purpose, all side-chain rotatable bonds have been rotated using an interval of 60°; the resulting conformations have been optimized after the elimination of all the constraints. The comparison of all of the optimized conformers to each other allows us to identify those that are energetically and geometrically unique.
Two main conformational families could be identified depending on the orientation of the carbonyl group; in one of them (type I), the oxygen atom points toward the methoxy group, and in the other (type II), it is orientated in the opposite direction, toward the 2′-NH 2 group. Figure 2 shows as an example the most stable conformer of each type of family for 4a, the metabolite of melatonin.
In general, conformations of family II are stabilized by the formation of an intramolecular hydrogen bond between the CO and the NH 2 moieties, whereas conformations belonging to family I are more energetic.
For 4a-i, there exists a higher number of conformations due to the existence of rotamers around the C-OMe bond. 4c (R 2 ) Pr) and 4d (R 2 ) Bu) have not been studied due to the high number of conformations expected (46.656 and 279.936, respectively), but the conformational behavior must be similar to that of the analogues with smaller side chains.
The comparison of all conformers of kynurenamines 4 with those of pyrazolines 3 using the benzene ring, the 2′-NH 2 group, and the oxygen atom of the amide terminal group demonstrates that a low-energy conformation of kynurenamines can be superimposed on our pharmacophore model in a way similar to that of kynurenines. Table 2 shows some data of the conformational behavior of these compounds, among them the total number of conformers, the range of relative energies comprising all conformations, the relative energy of the most stable conformer of each family, and the relative energy of the conformation that matches the pharmacophore model.
The active conformation belongs in all cases to the family II of conformations and in general is more stable than the preferred type I conformation. Only in 4i and 4l is the energy of the pharmacophoric conformation higher, but it could be due to an additional stabilization of conformations type I and II due to a π-π stacking interaction between both benzene moieties ( Figure 2) . Figure 3 shows as an example the superposition of 4a and 3a. It can be observed that the benzene ring, the 2′-NH 2 group, and the terminal amide oxygen atom coincide very well (RMSD ) 0.53 Å). Furthermore, the energy of this conformation of 4a is only 2.75 kcal/mol, a value that can be easily compensated by the enzymeligand interaction. In general, all studied compounds match the pharmacophore with conformations of low energy (Table 2 ).
This superimposition shows that the R 2 substituent in kynurenamines 4 is orientated in a way similar to that in kynurenines 2, that is toward the more hindered zone of the interaction model, and this orientation justifies the fact that the inhibition activity decreases when the volume of R 2 increases. In kynurenamines 4, the influence of R 2 over the biological activity is even clearer than in kynurenines, because only two derivatives (2a and 2b) were synthesized and tested in this family, whereas 12 kinurenamines (4a-4l) have been prepared. The influence of an increment of R 2 volume is also independent of the R 1 nature, and consequently, the structure-activity relationships found for kynurenamines 4 confirm our model for the interaction with nNOS.
The comparison of the activity of kynurenines 2a and 2b with that of their corresponding kynurenamine derivatives 4a and 4c (Table 1) indicates a slightly higher inhibition activity for compounds of type 2. Nevertheless, the differences in activity are not high enough to consider that kynurenines are more potent as nNOS inhibitors.
Conclusions
Kynurenamines 4 show good nNOS inhibition, showing structure-activity relationships similar to those of kynurenines 2, and as a whole, pyrazoline derivatives 3 are better nNOS inhibitors than 2 or 4. Our pharmacophore model fulfills all of the SARs for the three families of compounds and supports the results obtained in the kynurenamine family. Among these compounds, the melatonin metabolite aMK (4a) is the more-potent nNOS inhibitor.
Experimental Section
Melting points were determined using an Electrothermal-1A-6301 apparatus and are uncorrected. 1 H NMR and 13 C NMR spectra were recorded on a Bruker AMX 300 spectrom- Relative energies correspond to the 2a or 4a conformation, and RMSD indicates the goodness of the superimposition considering the aromatic ring, the 2′-NH2 group, and the amide oxygen atom as fitting atoms. Red arc indicates the hydrophobic pocket of the benzene ring. Blue and red arrows indicate the interaction with the hydrogen-bond acceptor and donor residues, respectively. Pockets for allocation of the R 2 amide substituent are indicated by the green (kynurenines and kinurenamines) and orange (pyrazoles) arrows. Similar orientation of R2 in 2 and 4 justifies the observed structure-activity relationships. m/z 425.052029 (M + Na) + , calcd mass for C19H15ClN2O6Na: 425.051634 (deviation -0.9 ppm). Preparation of N-[3-(2-Nitrophenyl-5-substituted)-3-oxopropyl]alquil-amides, 10a-l. General Method. To a solution of 0.69 mmol of the corresponding phthalimide 7a,b in 20 mL of dry ethanol was added 0.1 mL (2.07 mmol) of 95% hydrazine. The mixture was heated at reflux for 4.5 h and then made acidic (pH g 2) with concentrated hydrochloric acid. Heating was continued for an additional hour, and after cooling, the resulting suspension was removed by filtration. The filtrate was diluted with an equal volume of water and then washed with ether. The ether washings were discarded, and the aqueous layer was rendered alkaline (pH g 10) with solid potassium hydroxide. Extraction with ether (2 × 25 mL), combination of the ethereal fractions, drying (Na 2SO4), filtration, and concentration gave the amine, which was dissolved in CH2Cl2. Then, Et3N (slight molar excess) and acetic anhydride or the corresponding acyl chloride (1 mol equiv) in CH2Cl2 were added dropwise with stirring at room temperature. This solution was stirred for 3 h. The resulting solid was filtered and washed with H2O, 10% aqueous HCl, 2 M NaOH, H2O, and brine. The filtrate was then dried (Na2SO4) and filtered, and the solvent was removed under reduced pressure. The rats were killed by cervical dislocation, and the striata were quickly collected and immediately used to measure NOS activity. Upon removal, the tissues were cooled in ice-cold homogenizing buffer (25 mM Tris, 0.5 mM DTT, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 10 µg/mL aprotinine, and 1 mM PMSF at pH 7.6). Two striata were placed in 1.25 mL of the same buffer and homogenized in a Polytron (10 s × 6). The crude homogenate was centrifuged for 5 min at 1000g, and aliquots of the supernatant were either stored at -20°C for total protein determination 31 or used immediately to measure NOS activity. The nNOS activity was measured by the Bredt and Snyder 32 
Striatal KYN3OH Activity Determination
L-Kynurenine, 3-hydroxykynurenine, sucrose, NADPH, DHBA, DMSO, perchloric acid, triethylamine, phosphoric acid, heptanesulfonic acid, and EDTA-Na 2 were obtained from Sigma-Aldrich (Spain). HPLC-grade acetonitrile was obtained from Panreac (Spain). The water used for the preparation of solutions was of Milli-RO/Q grade (Millipore Iberica, Spain). All remaining chemicals were of analytical grade and were purchased from Sigma-Aldrich (Spain).
Tissue for KYN3OH determination was prepared from rats killed by cervical dislocation. Striata were rapidly removed, washed in cold saline, homogenized in 8 vol of sucrose (0.31 M), and centrifuged at 10 000g for 30 min at 4°C. The pellets were rinsed in sucrose (0.32 M) and centrifuged twice. The obtained pellets were resuspended in 8 vol of 0.14 M KCl and 20 mM phosphate buffer at pH 7 and frozen to -20°C until the assay.
The KYN3OH activity was measured following the Carpenedo 33 method, monitoring the conversion of L-kynurenine to 3-hydroxykynurenine. The final incubation volume was 120 µL and consisted in 100 µL of crude homogenate added to the buffer to give a final concentration of 0.1 M phosphate, 4 mM MgCl 2 , and 100 µM L-kynurenine. This solution was completed with 10 µL of 40 mM NADPH and 10 µL of each pyrazole derivative at a final concentration of 1 mM in DMSO. The tubes were vortexed and incubated at 37°C for 60 min. The reaction was stopped, the tubes were placed on ice, and 100 µL of cold 1 M perchloric acid was added. To this mixture was added 10 µL DHBA as internal standard, and the samples were centrifuged at 12 000g for 10 min at 4°C. The supernatant was removed and frozen to -20°C until 3-hydroxykynurenine determination. The concentration of 3-hydroxykynurenine was quantified by HPLC with electrochemical detection, following the method of Heyes and Quearry 34 with slight modifications. Separation was done in a C-18 reversed-phase 3-µm sphere analytical column. The applied potential was set at +0.6 V using a glass carbon electrode versus an Ag/AgCl reference electrode. The mobile phase consisted of 20 mL of acetonitrile, 9 mL of triethylamine, 5.9 mL of phosphoric acid, 100 mg of EDTA-Na 2 , and 1.8 g of heptanesulfonic acid in 1000 mL of deionized water. The solution was filtered through a 0.45-µm filter and degassed before use. Analyses were done at a flow rate of 1 mL/min at room temperature. The concentration of 3-hydroxykynurenine was calculated using DHBA as the internal standard and a calibration curve obtained from the corresponding standard injected in the HPLC system. The calculated concentration is expressed as nmol/h/g wet brain.
Statistical Analysis
Data are expressed as the mean ( SEM. One-way analysis of variance, followed by the Newman-Keuls multiple range test, was used. A P < 0.05 value was considered statistically significant.
